By P. Chen, F. Eyzaguirre, T. Francis, and J. Shmuel, Fish & Richardson
This is the fourth article in a four-part series on 2019 legal developments related to the biosimilar sector. In this final installment we cover 2019 biosimilar litigation related to anticompetitive conduct and post-grant patent challenges at the Patent Trial and Appeal Board (PTAB), and we look ahead to what biosimilar developers can anticipate in 2020.
With all the promise biosimilars hold, why are we not seeing increased market uptake? There are many reasons that involve policy, legislation, and the legal system that have led to the current state of the biosimilar market in the U.S. This white paper examines the basics.